Gout Treatment Guidelines Revamped After New Clinical Guidance

The updated 2020 guidelines from the American College of Rheumatology focus on establishing a standard treat-to-target urate lowering therapy.

3:08 PM

Author | Jordyn Imhoff

drawing of stethoscope
Image by Stephanie King.

Since the American College of Rheumatology last released the treatment guidelines for gout in 2012, new clinical evidence based on the latest clinical trials has prompted releasing updated guidelines that will improve patient care for the affected population. Standardization of a treat-to-target strategy for urate lowering therapy is the key focus because of its benefit for all patients with gout.

Gout, the most common form of inflammatory arthritis, is a painful, potentially disabling condition caused by having too much uric acid in the body. Uric acid buildup causes chronic inflammation leading to damage in the joints.

"The guidelines include expanded implications for starting urate lowering therapy and a greater emphasis to use allopurinol as the first line agent for all patients with gout that require urate lowering therapy, including those patients with chronic kidney disease," says Puja Khanna, M.D., MPH, a rheumatologist at Michigan Medicine. "It also broadened recommendations about who needs HLA-B*5801 testing prior to starting allopurinol." HLA-B*5901 is a genetic risk factor in specific populations.

The new guidelines recommend a management strategy of starting with a low-dose of a urate lowering medication and increasing the dosage to achieve and maintain a serum urate level of less than 6 mg/dL. This strategy, compared to the 2012 fixed-dose strategy, reduces the risk of treatment-related adverse effects, like flares and other side effects. Other recommendations include:

  • Using an anti-inflammatory prophylaxis (e.g., colchicine, NSAIDs, prednisone/prednisolone) when starting urate lowering therapy for at least three to six months rather than less than three months.
  • Considering urate lowering therapy for patients with infrequent gout flares or after their first gout flare if they also have moderate to severe chronic kidney disease (greater than or equal to stage three), marked hyperuricemia (serum urate greater than 9 mg/dL) or kidney stones.

The guidelines were developed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology. The updated and expanded recommendations can be viewed at American College of Rheumatology.

More Articles About: Lab Notes Health Care Delivery, Policy and Economics Arthritis Rheumatology
Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of healthcare news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]


Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Featured News & Stories drawing of pills in blue ink with lab note written on bottom right in yellow and navy blue
Health Lab
Patient Support Programs for Painful Conditions May Reduce Opioid Use
Study in people taking a biologic drug for autoimmune diseases shows association of patient support programs with reduced chance of starting opioid pain medicines or continuing on them.
Illustration of girl with blue water line, depicting a figure drowning, as girl contemplates pill in hand
Health Lab
Antidepressant dispensing to adolescents and young adults surges during pandemic
Rate of antidepressant dispensing to young people rose faster after March 2020, especially among females
Scale pictured behind a hospital room curtain
Health Lab
Obesity care can make a big difference, but few get it, study suggests
Obesity care under a health care provider’s supervision, whether through nutrition counseling, medication, meal replacement or bariatric surgery, can help people with high BMI, but many don’t receive it.
Woman in pink shirt lifts kettleball in an outdoor exercise class
Health Lab
How to make cancer prevention more equitable
Expert explains six behavioral risk factors for cancer and why current programs don’t always meet the needs of people from racially and ethnically minoritized groups and other vulnerable populations.
Woman sleeping on a couch holds her stomach, as if in pain
Health Lab
Long COVID-19 is linked to chronic pain conditions
Therapies for pain conditions like fibromyalgia provide clues for helping those with long COVID-19
Dark staircase leading to blue sky above
Health Lab
Ketamine’s promise for severe depression grows, but major questions remain
New findings about the impact of IV ketamine on treatment resistant depression add more fuel to the potential for broader use and insurance coverage.